Shihuida Pharmaceutical Group Enterprise Scale

The production base of the group is located at the foot of the beautiful Changbai Mountain, covering an area of 42,000 square meters, with a building area of 2 1000 square meters, with an annual output of 4 billion tablets. The Group has eight world-class production lines for tablets, capsules and ointments. One class of new drugs with independent intellectual property rights 1 piece, and two class of new drugs; One class of new drugs under development 1 piece, four class of new drugs; Two new drugs were patented in the United States, Germany, France, Britain, Canada and Australia, forming a drug framework for treating hypertension, hyperlipidemia and hyperglycemia.

Shihuida Pharmaceutical Group attaches great importance to talents, fully implements the talent strategy, and realizes the leap-forward sustainable development of enterprises. The Group has a high-quality team consisting of 26 experts and an academic advisory group, with nearly 1000 main managers and technicians, of which 93% have college education or above, 76% have professional technicians such as doctors and masters, and 19% have intermediate education or above. The Group has established long-term cooperative relations with many well-known scientific research institutions such as Peking University, Shanghai Jiaotong University and Huazhong University of Science and Technology, and has undertaken the "2 1 1 project" of the Ministry of Education, the "Eleventh Five-Year Plan" project of the Ministry of Health and the "863" project of the Ministry of Science and Technology, and published nearly 600 academic papers.

Enterprises actively repay the society, and have successively invested nearly 100 million yuan to set up the "Shihuida Scientific Research Fund" to support national scientific research, the "Shihuida Rescue Fund" to support the construction of disaster-stricken areas and help children with congenital heart diseases, and the "Shihuida Education Fund" to support the Chen Yun Education Fund to help poor children and minority children go to school.

For the rapid development of national medicine industry, enterprises recruit scientific research talents from China and actively develop independent and innovative biological drugs, chemical drugs, modern Chinese medicines and health products. After 2-3 years' efforts, there will be 3-4 first-class new drugs on the market, forming a series of drugs for treating hypertension, hyperlipidemia and hyperglycemia and making more contributions to the national drug reform and people's health.

In 20 12 years, the benefits reached an output value of 65.438+0.85 billion yuan, sales exceeded 65.438+0.3 billion yuan, and taxes paid were 65.438+0.94 billion yuan. Compared with similar imported drugs, it saves nearly 654.38 billion yuan for the country and patients. By 20 15, the sales revenue will be 2 billion yuan and the tax revenue will be 400 million yuan. Created a miracle of national innovative medicine. According to the authoritative statistics of IMS and Southern Intelligence, Shi Huida ranks first in the sales and retail sales of antihypertensive drugs in China hospitals, and is the only China drug in the top ten. In the ranking of pharmaceutical enterprises in China in 20 12, Shihuida ranked first in Jilin Province in the income from the main business of listed drugs.